FDA holds back from action over Xeljanz safety studyThe FDA has said it will wait for additional results from last week’s trial showing an increased risk Share XFDA holds back from action over Xeljanz safety studyhttps://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/
Bad news for Pfizer as blockbuster Xeljanz flunks safety studyJAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and Share XBad news for Pfizer as blockbuster Xeljanz flunks safety studyhttps://pharmaphorum.com/news/bad-news-for-pfizer-as-blockbuster-xeljanz-flunks-safety-study/
